89 FR 171 pgs. 71927-71928 - Bulk Manufacturer of Controlled Substances Application: Benuvia Operations, LLC
Type: NOTICEVolume: 89Number: 171Pages: 71927 - 71928
Pages: 71927, 71928Docket number: [Docket No. DEA-1408]
FR document: [FR Doc. 2024-19795 Filed 9-3-24; 8:45 am]
Agency: Justice Department
Sub Agency: Drug Enforcement Administration
Official PDF Version: PDF Version
[top]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1408]
Bulk Manufacturer of Controlled Substances Application: Benuvia Operations, LLC
AGENCY:
Drug Enforcement Administration, Justice.
ACTION:
Notice of application.
SUMMARY:
Benuvia Operations, LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
DATES:
Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before November 4, 2024. Such persons may also file a written request for a hearing on the application on or before November 4, 2024.
ADDRESSES:
[top] The Drug Enforcement Administration requires that all
SUPPLEMENTARY INFORMATION:
In accordance with 21 CFR 1301.33(a), this is notice that on June 7, 2024, Benuvia Operations, LLC, 3950 North Mays Street, Round Rock, Texas 78665, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):
Controlled substance | Drug code | Schedule |
---|---|---|
Ibogaine | 7260 | I |
Marihuana Extract | 7350 | I |
Tetrahydrocannabinols | 7370 | I |
Mescaline | 7381 | I |
3,4-Methylenedioxyamphetamine | 7400 | I |
3,4-Methylenedioxymethamphetamine | 7405 | I |
5-Methoxy-N-N-dimethyltryptamine | 7431 | I |
Dimethyltryptamine | 7435 | I |
Psilocybin | 7437 | I |
Psilocyn | 7438 | I |
5-Methoxy-N,N-diisopropyltryptamine | 7439 | I |
The company plans to bulk manufacture the listed controlled substances for internal research and dosage formulation development. No other activities for these drug codes are authorized for this registration.
Marsha L. Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024-19795 Filed 9-3-24; 8:45 am]
BILLING CODE P